News & Updates

Show Multimedia Only
More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

More evidence supports enzalutamide’s link with poorer mood and cognitive outcomes in mCRPC

09 May 2024 byKanas Chan

Patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide reported more fatigue, depression and deterioration in perceived cognitive ability, and slower reaction time than those receiving abiraterone acetate, according to results of the ACE study.

09 May 2024